Prostate cancer in Brazil and Latin America: epidemiology and screening

Tourinho-Barbosa, Rafael; Pompeo, Antônio Carlos Lima; Glina, Sidney

doi:10.1590/s1677-5538.ibju.2015.0690

Cited by 35 publications

(34 citation statements)

References 13 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prostate cancer mortality rates in LA were higher compared to those of the EU and North America and are predicted to be among the highest worldwide. However, they showed favourable trends for most countries up to 2019, likely due to improvements in treatment, and early diagnosis . Similarly to other cancers, progress on prostate cancer was however smaller than in high‐income areas of the world.…”

Section: Discussionmentioning

confidence: 99%

Cancer mortality predictions for 2019 in Latin America

Carioli

Bertuccio

Malvezzi

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

We estimated mortality figures for 2019 in seven Latin American countries, with focus on breast cancer. We retrieved cancer death certification and population data from the WHO and PAHO databases. We obtained mortality statistics for Argentina, Brazil, Chile, Colombia, Cuba, Mexico and Venezuela for 1970-2015. We predicted current death numbers and agestandardised (world population) mortality rates using joinpoint regression models. Total cancer mortality is predicted to decline in all countries and both sexes, except Argentinian women. Cuba had the highest all cancer rates for 2019, 136.9/100,000 men and 90.4 women, while Mexico showed the lowest ones, 63.8/100,000 men and 61.9 women. Stomach cancer showed favourable trends over the whole period, while colorectal cancer only recently. Lung cancer rates declined in men, while in women they decreased slightly over the most recent years, only. In Cuban women, lung cancer rates overtook breast cancer ones. Breast cancer showed overall favourable trends, but rates are rising in young women. Prostate and uterine cancer had favourable trends. Pancreas, ovary, bladder and leukaemias showed slightly decreasing trends. Between 1990 and 2019, mortality from all neoplasms is predicted to fall by about 18% in Argentina, 26% in Chile, 14% in Colombia, 17% in Mexico and 13% in Venezuela, corresponding to almost 0.5 million avoided cancer deaths. No decline was observed in Brazil and Cuba. Of concern, the persisting high rates of (cervix) uterus cancer, the high lung cancer rates in Cuba, the possible increases in breast cancer in young women, and the lack of overall declines in Brazil, Cuba and Venezuelan men. Materials and MethodsWe obtained official deaths certification data from the World Health Organization (WHO) database 10 for all cancers combined and for 10 major cancer types, i.e., stomach, colorectum, pancreas, lung, breast, uterus (cervix and corpus), ovary, prostate, bladder and leukaemias. We retrieved data for the period between 1970 and 2015 for LA countries with over Additional Supporting Information may be found in the online version of this article.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer mortality predictions for 2019 in Latin America

Carioli

Bertuccio

Malvezzi

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…For most LMICs, data collection related to incidence and mortality for prostate cancer has limited validity . In order to understand these patterns in Latin America, we conducted a literature search regarding prostate cancer in the region.…”

Section: Introductionmentioning

confidence: 99%

Prostate cancer mortality rates in Peru and its geographical regions

et al. 2018

View full text Add to dashboard Cite

ObjectiveTo evaluate the mortality rates for prostate cancer according to geographical areas in Peru between 2005 and 2014. Materials and MethodsInformation was extracted from the Deceased Registry of the Peruvian Ministry of Health. We analysed age-standardised mortality rates (world population) per 100 000 men. Spatial autocorrelation was determined according to the Moran Index. In addition, we used Cluster Map to explore relations between regions. ResultsMortality rates increased from ) per 100 000 men, an increase of 15.2%. According to regions, during the period 2010-2014, the coast had the highest mortality rate (28.9 per 100 000), whilst the rainforest had the lowest (7.43 per 100 000). In addition, there was an increase in mortality in the coast and a decline in the rainforest over the period 2005-2014. The provinces with the highest mortality were Piura, Lambayeque, La Libertad, Callao, Lima, Ica, and Arequipa. Moreover, these provinces (except Arequipa) showed increasing trends during the years under study. The provinces with the lowest observed prostate cancer mortality rates were Loreto, Ucayali, and Madre de Dios. This study showed positive spatial autocorrelation (Moran's I: 0.30, P = 0.01). ConclusionMortality rates from prostate cancer in Peru continue to increase. These rates are higher in the coastal region compared to those in the highlands or rainforest. Epidemiology ANCASHAPURIMAC AREQUIPA AYACUCHO Fig. 4 Trends in ASMRs (world population) per 100 000 men from prostate cancer in all provinces of Peru.

show abstract

“…( 3 ) Although the lack of data in Brazil, it is hypothesized that there will be a greater proportion of metastatic disease reported at diagnosis due to socioeconomic reasons. ( 4 )…”

Section: Introductionmentioning

confidence: 99%

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer

Aguiar

Barreto

Gutierres

et al. 2017

Einstein (São Paulo)

View full text Add to dashboard Cite

Objective To assess the cost-effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer.Methods An analytical decision model was developed to determine the cost-effectiveness of chemohormonal therapy versus androgen deprivation therapy alone in patients with metastatic hormone-sensitive prostate cancer and patients with non-metastatic high-risk prostate cancer. The cost-effectiveness in metastatic patients with a high-volume disease was assessed separately. The model used data from randomized clinical trials and drug acquisition costs in Brazil. In addition, the costs of post-progression therapies have been included in this model. The benefits to health are expressed as the quality-adjusted life-years, and the incremental cost-effectiveness ratios were calculated.Results Chemohormonal therapy may be associated with improved quality-adjusted life-years for all patient. The improvement was more than six times greater for patients with high-volume metastatic disease. In these patients, the incremental cost-effectiveness ratios were up to 74% lower than the incremental cost-effectiveness ratios of patients with non-metastatic disease.Conclusion Chemohormonal therapy has been more cost-effective in patients with high-volume metastatic disease.

show abstract

Prostate cancer in Brazil and Latin America: epidemiology and screening

Cited by 35 publications

References 13 publications

Cancer mortality predictions for 2019 in Latin America

Cancer mortality predictions for 2019 in Latin America

Prostate cancer mortality rates in Peru and its geographical regions

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer

Contact Info

Product

Resources

About